UBP
SYRE icon

Union Bancaire Privee’s Spyre Therapeutics SYRE Stock Holding History

Union Bancaire Privee’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.3K Sell
880
-3,000
-77% -$219K ﹤0.01% 422
2026
Q1 		$159K Buy
+3,880
New +$146K ﹤0.01% 401

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Union Bancaire Privee's SYRE Position: Q2 2026 in Review

Union Bancaire Privee reduced its Spyre Therapeutics (SYRE) stake by 77% in Q2 2026, selling an estimated $219K and leaving 880 shares worth $79.3K. The position accounts for ﹤0.01% of the portfolio, ranked #422.

Union Bancaire Privee first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. The position peaked at $159K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Union Bancaire Privee held 880 shares of Spyre Therapeutics worth $79.3K as of Q2 2026.
  • Union Bancaire Privee sold 3,000 Spyre Therapeutics shares in Q2 2026, an estimated $219K.
  • Spyre Therapeutics made up ﹤0.01% of Union Bancaire Privee's portfolio in Q2 2026, its #422 holding.
  • Union Bancaire Privee first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Union Bancaire Privee's Spyre Therapeutics position peaked at $159K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Union Bancaire Privee's 13F filing for Q2 2026, filed 16 Jul 2026.